康莱特注射液辅助PD-1/PD-L1抑制剂联合化疗治疗非小细胞肺癌的临床疗效观察  

Clinical Efficacy Observation of Kanglaite Injection Combined with PD-1/PD-L1 Inhibitors and Chemotherapy in Treatment of Non-Small Cell Lung Cancer

作　　者：刘拥军 杨荣禄 李正[2] 朱伟明 李金虎 孙凡 LIU Yongjun;YANG Ronglu;LI Zheng;ZHU Weiming;LI Jinhu;SUN Fan(Department of Traditional Chinese Medicine,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Department of Pharmacy,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Department of Radiotherapy,Jimin Tumor Hospital Affiliated to Anhui Medical University,Hefei 230001,China)

机构地区：[1]中国科学技术大学附属第一医院(安徽省立医院)中医科,安徽合肥230001 [2]中国科学技术大学附属第一医院(安徽省立医院)药学部,安徽合肥230001 [3]安徽医科大学附属济民肿瘤医院放射治疗科,安徽合肥230001

出　　处：《现代中药研究与实践》2024年第4期87-91,共5页Research and Practice on Chinese Medicines

摘　　要：目的观察康莱特注射液(KLTI)辅助PD-1/PD-L1抑制剂联合化疗一线治疗非小细胞肺癌(NSCLC)的临床疗效和安全性,为临床治疗NSCLC提供依据。方法纳入2020年01月至2023年12月中国科学技术大学附属第一医院收治的NSCLC患者共64例,根据是否使用KLTI分为观察组(30例)和对照组(34例),比较两组患者客观缓解率(ORR)、疾病控制率(DCR)、KPS评分、肿瘤标志物(CEA、CYFRA21-1)及不良反应。结果与对照组相比,观察组ORR、DCR、KPS评分差异无统计学意义(P>0.05),肿瘤标志物CEA和CYFRA21-1治疗前、后下降幅度显著(P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论KLTI辅助PD-1/PD-L1抑制剂联合化疗一线治疗NSCLC能降低患者血清CEA、CYFRA21-1水平,且安全可靠。Objective To observe the clinical efficacy and safety of Kanglaite Injection(KLTI)combined with PD-1/PD-L1 inhibitors and chemotherapy in the first-line treatment of non-small cell lung cancer(NSCLC),providing a basis for the clinical treatment of NSCLC.Methods A total of 64 NSCLC patients admitted to the First Afiliated Hospital of the University of Science and Technology of China from January 2020 to December 2023 were included.They were divided into observation group(30 cases)and control group(34 cases)based on whether KLTI was used.The objective response rate(ORR),disease control rate(DCR),KPS score,tumor markers(CEA,CYFRA21-1),and adverse reactions were compared between the two groups.Results Compared with the control group,there was no statistically significant difference in ORR,DCR and KPS scores in the observation group(P>0.05).The decrease in tumor markers CEA and CYFRA21-1 before and after treatment was significant(P<0.05);There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion KLTI assisted PD-1/PD-L1 inhibitor combined with chemotherapy for firstline treatment of NSCLC can reduce serum CEA and CYFRA21-1 levels,improve physical condition to a certain extent,enhance quality of life,and is safe and reliable.

关 键 词：康莱特注射液 PD-1/PD-L1抑制剂 化疗 非小细胞肺癌 

分 类 号：R285.6[医药卫生—中药学]